Leap Therapeutics (NASDAQ:LPTX) Raised to Buy at Zacks Investment Research

Leap Therapeutics (NASDAQ:LPTX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, January 3rd. The firm currently has a $7.00 target price on the stock. Zacks Investment Research‘s target price indicates a potential upside of 11.46% from the company’s current price.

According to Zacks, “Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. “

Shares of Leap Therapeutics (LPTX) traded up $0.06 on Wednesday, hitting $6.28. The stock had a trading volume of 27,422 shares, compared to its average volume of 51,599. Leap Therapeutics has a fifty-two week low of $4.90 and a fifty-two week high of $10.10.

Leap Therapeutics (NASDAQ:LPTX) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.11). research analysts anticipate that Leap Therapeutics will post -3.63 earnings per share for the current fiscal year.

In other Leap Therapeutics news, COO Augustine Lawlor bought 1,057,769 shares of the company’s stock in a transaction on Tuesday, November 14th. The stock was bought at an average price of $6.09 per share, for a total transaction of $6,441,813.21. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 58.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Leap Therapeutics (NASDAQ:LPTX) Raised to Buy at Zacks Investment Research” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/13/leap-therapeutics-lptx-upgraded-at-zacks-investment-research.html.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply